Danielle M. Brander

translational oncologist at Duke Cancer Institute / director CLL & Lymphoma research program / views and tweets are my own

[Duke Health @DukeHealth]

CME Opportunity: Join #DukeDebates2024, presented by #DukeCancerNetwork in collaboration with @DukeCancer.

April 12-14, 2024, Hilton Head, SC

Register here: https://t.co/yOJ9bo9fc3

CME credit available. Earn up to 12 MOC Part 2 points.

#DukeCancerInstitute #MedEd

[Danielle M. Brander @dbranderMD]

@KrishPatelMD @NitinJainMD @ASkarbnik @mshadman @DrMDavids @DanilovLab @DebbieMStephens @RyanWJacobs @LoriLeslieMD @AdamKittai @BrianHill_MDPhD @andrewlipskymd @calliecoombsmd Yes this! Also reason for early referrals even when therapy is “working” to start these conversations and provide time for patients/caregivers to make these informed decisions

[Danielle M. Brander @dbranderMD]

@mshadman @NitinJainMD @ASkarbnik @DrMDavids @DanilovLab @DebbieMStephens @RyanWJacobs @LoriLeslieMD @AdamKittai @BrianHill_MDPhD @andrewlipskymd @calliecoombsmd @KrishPatelMD Agree - Also would consider CART in fit informed pts early relapse post ven if prior cBTKi failure & low disease burden/control. Similar to other cellular tx suspect meaningful longer term efficacy will be about disease control & burden going into CART > than traditional markers

[Danielle M. Brander @dbranderMD]

@MrazLab Amazing - congratulations!! So honored to have known you these years and witness all you’ve accomplished.

[Deborah Stephens @DebbieMStephens]

Ask your doctor if you are considered high risk by the CLLIPI score. If so, you may qualify for this exciting study. #CLL @SWOG @BrianHill_MDPhD @mshadman @anthonymatomd @dbranderMD @DanilovLab

[Matthew Davids, MD, MMSc @DrMDavids]

Outstanding commentary by ⁦@DebbieMStephens⁩ from ⁦@huntsmancancer⁩ on the recent publication on the ELEVATE-RR study comparing ibrutinib and acalabrutinib in R/R CLL in ⁦@JCO_ASCO⁩ https://t.co/jtMU2RQYub

[Danilov Lab @DanilovLab]

Just out - our multicenter effort to dissect comorbidities in CLL ⁦@mshadman⁩ ⁦@DrDanPersky⁩ ⁦@dbranderMD⁩ ⁦@matthew_mei⁩ ⁦@jonathonbcohen⁩ ⁦@KrishPatelMD⁩ ⁦@BrianHill_MDPhD⁩ ⁦@DebbieMStephens⁩ https://t.co/euUhVR5LZb

[Deborah Stephens @DebbieMStephens]

Thanks to the @CllSociety for all you do for our patients. Happy New Year!

[Toby Eyre @tobyeyre82]

Important MURANO tox ax
@anthonymatomd @jeff_sharman et al
28% premature d/c VR<2y
⬇️ PFS in prem d/c ven for any reason (PD excluded;p<0.0001)+due to AE

Interrupt for AE 69% / dose ⬇️ 23% both no impact on PFS/OS

Tox mx+continued Rx important for VenR PFS outcome #CLL #lymsm

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

#ASH20 poster by @LindsayReinMD @DukeHMCT @dukemedicine @DukeCancer

Phase I trial incorporating NK cells for patients w/ #CML & MRD after TKI therapy. #leusm

https://t.co/skRtQa5DCw

[Danielle M. Brander @dbranderMD]

There may not have been an official ASH run this year, but anyone else still get in their #FauciFour ? If daily running is the secret to Dr Fauci leading the nation through this chaos, may I never stop.

Also, the San Diego skyline has nothing on my view.
#IRunForASH

[Danielle M. Brander @dbranderMD]

@DukeHMCT @DukeFellows @DukeCancer

[Danielle M. Brander @dbranderMD]

Flashback Friday and my upcoming first Twitter-versary.

This tweet from an amazing #cll leader, along with a little help from @chadinabhan and @anthonymatomd finally got me on board. Looking forward to #ash20 highlights and my first ash on Twitter.

[Danielle M. Brander @dbranderMD]

@cmpabon Well said! Also sad that even when insurance “covers” - most patients are very much underinsured and co pays are limiting.

[Danielle M. Brander @dbranderMD]

To teach is to learn, twice

And thankful for this opportunity from #ASH20, twice -
to learn from so many others but also to work on this with an amazing fellow @DukeFellows, Dr Ashley Hanlon @amilliga, that has taught me so much and co authored this chapter #dukefamily

[Danielle M. Brander @dbranderMD]

@tomleblancMD @DukeCancer @DukeHMCT Thanks for the support!

[Duke HemeOnc Fellows @DukeFellows]

We are so excited to welcome @_joycehwang @andrewpeseski @FahminB_MDPhD Drs. Kathrine DiNardo, Cameron Oswalt, Grayce Selig, and Cameron Wood to the Duke Heme/Onc Fellowship Program! We are so excited to have you join our wards and clinics in July 2021! @DukeCancer @dukemedicine

[Danielle M. Brander @dbranderMD]

Intolerance is a failure of the medication for that given patient, patients don’t fail therapy.

Grateful to be a part of this collaborative effort @DukeHMCT and for all trials aimed at the unmet need of intolerance. @anthonymatomd @AndreaSitlinger and many others